Summary
- Profile Type
- Technology offer
- POD Reference
- TOIT20260811029
- Term of Validity
- 11 August 2026 - 11 August 2027
- Company's Country
- Italy
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
General information
- Short Summary
- An Italian life-science AI start-up offers a pilot-ready platform for structure-based small-molecule design and optimisation. The solution combines multi-agent AI, chemoinformatics, molecular modelling, and simulation in traceable workflows, with a strategic focus on Antimicrobial Resistance (AMR). The company seeks pharma, biotech, CRO, research and specialist commercial partners for pilots, services, technical cooperation and co-development.
- Full Description
-
The Italian company develops computational technology for structure-based small-molecule design and optimization. Its current strategic focus is Antimicrobial Resistance (AMR), where new molecular candidates and more efficient discovery workflows are urgently needed. The company combines software engineering, molecular biology, multi-agent artificial intelligence, chemoinformatics and computational chemistry to develop new drugs and support scientific teams in the early stages of molecular discovery.
The offered technology is a modular, pilot-ready platform that can support target and binding-pocket analysis, guided molecule generation and optimisation, physicochemical and developability assessment, similarity and novelty analysis, molecular docking, optional molecular-dynamics workflows, candidate ranking and decision-oriented reporting. Specialised AI agents coordinate the workflow, while established scientific tools perform deterministic calculations and evaluations. Inputs, parameters, intermediate results, assumptions and limitations are documented to improve traceability and reproducibility.
The platform is intended to reduce fragmented hand-offs between disconnected tools and to help R&D teams prioritize which compounds should progress to expert review, synthesis and biological testing. It does not replace medicinal chemistry, microbiology or wet-lab validation, and no therapeutic efficacy is claimed without experimental evidence.
The solution can be delivered through a scoped paid pilot, a managed computational R&D service, technical cooperation, or a configurable integration with a partner workflow. Core modules are available for demonstration and have been tested in internal end-to-end R&D workflows. Pilot scope, success criteria, data governance, confidentiality and intellectual-property allocation are agreed with each partner.
The company seeks: (i) pharma and biotech organisations with AMR programmes or relevant bacterial targets; (ii) CROs and specialised life-science service providers wishing to extend their computational discovery capabilities; (iii) universities, research centres and translational organisations able to contribute scientific expertise or experimental validation; and (iv) specialist commercial or technology partners with an established network in pharmaceutical and biotechnology R&D. Cooperation may involve pilot projects, service delivery, co-development, integration, validation or joint R&D initiatives. - Advantages and Innovations
-
The main innovation is the orchestration of specialised AI agents with established computational chemistry and chemoinformatics methods in one traceable workflow for structure-based small-molecule design. The system is designed for practical scientific use rather than generic text generation.
Key advantages include:
- End-to-end support from a biological target and binding pocket to ranked molecular candidates and a documented follow-up plan.
- Combination of multi-agent reasoning with deterministic scientific calculations, validation rules and human review.
- Reproducible records of inputs, parameters, assumptions, outputs and limitations.
- Configurable optimization objectives and constraints for partner-specific discovery programmes.
- Integration of molecule generation, property assessment, novelty checks, docking, simulation analysis and reporting.
- Modular delivery as a paid pilot, managed service or technical integration, with support for confidential partner data.
- Strategic specialisation in AMR and structure-based discovery against bacterial targets.
- Improvement of compound value over time based on previous experiments.
- Capabilities for lead optimization.
- Advanced computational chemistry analysis to validate targets and ligand-posed complex stability.
The platform can reduce manual hand-offs between separate tools and improve the consistency of computational prioritisation before synthesis and biological testing. Final scientific and development decisions remain under expert control and require experimental validation. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- Protection is currently based on copyright in the software, source code and documentation, together with confidential know-how covering workflow design, agent orchestration, configurations and internal methods. No patent is claimed in this profile. Partner data, targets, molecules, results and project-specific developments can be governed by NDA and by collaboration-specific background-IP and foreground-IP terms.
Partner Sought
- Expected Role of a Partner
-
The company seeks qualified commercial, technological and R&D partners for the adoption, validation and delivery of its AI-assisted structure-based small-molecule design platform, with a strong focus on Antimicrobial Resistance (AMR).
Priority partner profiles:
- Pharma and biotech companies with AMR discovery programmes, validated bacterial targets, compound series or unmet computational-design needs.
- CROs and specialised life-science service providers seeking to add or strengthen AI-assisted molecular design, docking, simulation and prioritisation services.
- Universities, Hospitals, research centres, microbiology laboratories, medicinal-chemistry groups and translational organisations interested in co-development, experimental validation or European R&D projects.
- Specialist life-science technology integrators, consultants and commercial partners with an established network of relevant pharmaceutical, biotechnology and CRO decision-makers.
Expected role of end-user and R&D partners:
- Define a relevant target, compound series, dataset or scientific use case and agree measurable pilot objectives.
- Contribute domain expertise, reference data and, where applicable, medicinal-chemistry, microbiology, synthesis or assay capabilities.
- Review computational results and experimentally validate prioritised candidates when the project includes validation.
- Explore longer-term service, integration, co-development or research cooperation following a successful pilot.
Expected role of specialist commercial partners:
- Identify and qualify suitable opportunities within an established life-science R&D network.
- Support local introductions, market development and stakeholder coordination.
- Participate in a technically informed go-to-market approach rather than generic software resale.
The company provides scientific and technical scoping, platform access or workflow execution, computational analysis, reporting, onboarding and integration support. Generic IT resellers without life-science expertise or access to relevant R&D end-users are not sought. - Type and Size of Partner
- R&D Institution
- SME <=10
- Other
- University
- SME 50 - 249
- Big company
- SME 11-49
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001015 - Pharmaceutical Products / Drugs
- 06002002 - Cellular and Molecular Biology
- 06002009 - Molecular design
- 05001002 - Computational Chemistry and Modelling
- 01003003 - Artificial Intelligence (AI)
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05001005 - Molecular diagnosis
- 04014 - Bioinformatics
- 04006 - Cellular and Molecular Biology
- 04010 - Microbiology
- Sector Groups Involved
- Health
- Targeted countries
- All countries
Files
Academic Publication involving Neoralab's staff